- Home
- ZNTL vs CATX Comparison
ZNTL vs CATX Comparison
Compare ZNTL & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | CATX |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 341.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | CATX |
|---|---|---|
| Price | $4.11 | $3.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $6.60 | ★ $12.11 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.21 | $1.96 |
| 52 Week High | $6.95 | $6.16 |
Technical Indicators
Market Signals| Indicator | ZNTL | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 55.02 |
| Support Level | $3.53 | $2.82 |
| Resistance Level | $4.23 | $4.27 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 13.60 | 92.86 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.